Company / Working Capital
Tandem Diabetes Care Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$375.4M
FY2025
5-year range
$375.4M / $684.7M
FY2021-FY2025
Trend
-21.4%
vs FY2024
Sector context
#78 of 160
Health Care
What the data says
At $375M, Tandem Diabetes Care's working capital ranks #78 of 160 in the Health Care sector. Working Capital has declined for 3 consecutive years, from $685M in FY2022 to $375M in FY2025.
Based on SEC 10-K filings.
$375M in FY2025 with a 5-year CAGR of -6.8%.
Declined from $553M to $375M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -18.2%
- 5-Year CAGR
- -6.8%
- 10-Year CAGR
- -
Sector benchmark
#78 of 160 in Health CareTop 49% of 160This company $375.4M Sector average $757.1M
▼
-50.4% below sector average
Key checks
Key Insights
- Tandem Diabetes Care's working capital has declined for 3 consecutive years.
- 5-year CAGR of -6.8%, indicating a declining trend.
- In FY2025, working capital decreased 21.4% year-over-year.
- Ranks #78 out of 160 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.32 (distress zone, below 1.8 threshold)
- Negative profit margin: -20.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $375.4M | -21.4% |
| FY2024 | $477.4M | -13.6% |
| FY2023 | $552.7M | -19.3% |
| FY2022 | $684.7M | +0.7% |
| FY2021 | $679.7M | +27.4% |
| FY2020 | $533.4M | +201.8% |
| FY2019 | $176.7M | +45.4% |
| FY2018 | $121.6M | +333.2% |
| FY2017 | $28.1M | -53.7% |
| FY2016 | $60.6M | -24.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026